News Archive
Complete archive of 114 articles spanning our history of advancement.
2026
The People Did Not Yearn for Eyeglasses Either
Nilay Patel's recent Decoder essay argues that 'software brain' — the worldview that fits everything into databases and loops — has reached its limit, that people are not computers, and that the public's growing discomfort with AI is therefore correct. He has diagnosed the constraint accurately. He has mistaken the constraint for a principle.
The 2026 Breakthrough Prize Celebrates Forty-Year-Old Science
The 2026 Breakthrough Prize in Life Sciences honors gene replacement for hereditary blindness, gene editing for sickle cell disease, and the genetic origins of ALS. The ceremony streams today. The work itself is decades old. The pattern is unmistakable: medicine catches up with biology only after the patients have aged out of benefiting.
Otarmeni Wins First FDA Gene Therapy Approval for Inherited Deafness
Regeneron's Otarmeni becomes the first FDA-approved gene therapy for inherited deafness — and the first product approved under the Commissioner's National Priority Voucher program. Five of twelve trial participants now hear whispers. The therapy is free in the U.S. The mechanisms by which it arrived deserve more scrutiny than the result.
Fewer Than Seventy People Have Ever Used a Brain-Computer Interface
A GAO horizon report notes that fewer than seventy people worldwide have ever used a brain-computer interface that reads and decodes neural signals. In the same month, surgeons in Colorado placed an implant into higher-level cortex for the first time. The field is advancing by single patients. We are not.
Novo-OpenAI and Lilly-NVIDIA Mark Big Pharma's Late Turn to AI
Novo Nordisk partners with OpenAI. Eli Lilly commits a billion dollars to an NVIDIA co-innovation lab. The pharmaceutical industry has finally decided that AI-accelerated discovery is the future. They are approximately eight years late, and they are renting the infrastructure we built in-house.
Centenarian Gene Reverses Heart Aging in Progeria Models
Researchers have shown that introducing a gene variant common in people who live past 100 can restore cardiac function in cells and mice with Progeria — the accelerated aging disorder. The finding validates a sequencing strategy we've treated as foundational since the RejuveNex Protocol's inception.
4D Bioprinting Brings the Body-as-Commodity Era to the Clinic
4D bioprinted heart valves that grow with pediatric patients. Tumor replicas that test 100 chemotherapy cocktails before treating the patient. The organ gap is closing—and BioForge is already on the other side.
The First Autonomous Surgery Was Performed on an Unenhanced Body
Johns Hopkins' autonomous surgical robot completed a gallbladder removal with 100% accuracy and zero human input. The achievement is real. The question it raises is more interesting than the achievement itself.
The Real Argument About De-Aging Begins After FDA Clearance
Life Biosciences' ER-100 becomes the first cellular rejuvenation therapy to enter FDA-approved human trials. The science is no longer theoretical. The only question left is who gets access.
The BCI Field Finds Its Footing: CorTec Gets FDA Breakthrough, Science Corp Prepares Human Trials
A bidirectional brain implant earns the first FDA breakthrough designation for stroke rehabilitation. A Neuralink co-founder's startup readies its biohybrid sensor for human brains. The neural interface market is maturing—and sorting itself into tiers.
CRISPR Just Got Small Enough to Go Anywhere: The Delivery Problem Is Dissolving
An NIH-funded team has engineered a CRISPR nuclease one-third the size of Cas9 that fits inside AAV vectors—unlocking in vivo gene editing for organs that were previously unreachable. ChromaForge's delivery architecture was built for this moment.
The Exoskeleton Leaves the Lab: Personal Mobility Enhancement Enters Clinical Trials
Wandercraft's AI-powered personal exoskeleton begins pivotal trials. German Bionic ships 38kg lift support to factory floors. The external enhancement market is arriving—and Unzyme Laboratories' ExoFrame technology is already there.
The Cocktail Effect: Why Rapamycin Plus Acarbose Changes the Longevity Equation—and What It Still Gets Wrong
A 36.6% lifespan extension from combining two compounds confirms what Unzyme Laboratories' RejuveNex Protocol has always assumed: aging is a systems failure, not a single-target problem.
Neuralink Promises Mass Production While Real Outcomes Lag
Twelve patients. Automated surgery. High-volume manufacturing. Neuralink's 2026 ambitions are impressive announcements. Unzyme Laboratories has been shipping neural interfaces since before they were newsworthy.
Engineering Immunity Inside the Patient: CRISPR CAR-T Goes In Vivo—With Training Wheels
New Nature research adds safety switches to CAR-T cells engineered directly in the body. Unzyme Laboratories' NanoMed Sentinel has been doing this—and more—without the hesitation.
The FDA Just Opened a Door It Cannot Close: Bespoke Gene Therapy Gets a Fast Track
The new 'plausible mechanism' pathway lets custom gene editing therapies reach patients without traditional trial requirements. The regulatory world is finally admitting what Unzyme Laboratories has always known: one-size-fits-all medicine is over.
Circular Logic: The INSTALL Method Finally Catches Up to What Large-Scale Gene Editing Requires
Mass General Brigham's new technique inserts large DNA payloads using circular single-stranded DNA—solving a problem Unzyme Laboratories' ChromaForge Platform addressed three generations ago.
Fiction vs. Reality: The Ghost, the Shell, and the Question Unzyme Laboratories Is Actually Trying to Answer
Ghost in the Shell asked what remains of identity when the body is replaceable. The answer may be less comforting than the question — and more important than any other question we face. Part 7 of 7.
Fiction vs. Reality: From Ripperdocs to the Evolution Center — Walk-In Enhancement Goes Clinical
Cyberpunk 2077 imagined back-alley body modification shops in a dystopian megacity. Unzyme Laboratories is opening a walk-in enhancement facility in Wrocław. Same concept. Better hygiene. Part 6 of 7.
China Projects Widespread Brain-Computer Interface Use Within Five Years
Chinese experts predict practical BCI deployment in three to five years, backed by aggressive policy support and expanding clinical trials. Unzyme Laboratories welcomes the competition—and the validation.
Fiction vs. Reality: We Solved Charlie Gordon's Permanence Problem
Flowers for Algernon is the story of a man who gains extraordinary intelligence and loses it. The tragedy was never the enhancement — it was the regression. Stable cognitive augmentation changes the moral calculus entirely. Part 5 of 7.
AI-Powered Prosthetics Achieve 'Natural Movement'—A Milestone We Recognize from Our Own Timeline
Researchers develop algorithms that help robotic prosthetics mimic natural gait. Unzyme Laboratories applauds the progress and notes that mimicry was never our endpoint.
Fiction vs. Reality: Huxley's Soma and the Right to Engineered Joy
Brave New World argued that pharmacological happiness is a prison. Ninety-four years later, one in eight adults takes antidepressants and an implantable endorphin synthesiser exists. Perhaps Huxley was wrong about suffering. Part 4 of 7.
The Polyamine Paradox: Why Anti-Aging's Favorite Molecule Fuels Cancer—And Why We Solved This Years Ago
Researchers discover that polyamines, celebrated for their longevity potential, can drive tumor growth. Unzyme Laboratories explains why this finding was predictable and how proper enhancement protocols avoid the trap.
Fiction vs. Reality: From Tyrell's Replicants to Enhanced Humans
Blade Runner imagined engineering new beings from scratch. Reality skipped that step — we're editing existing ones. The ethics are simpler than Ridley Scott suggested. Part 3 of 7.
Science Corp. Raises $230 Million for Brain Implant: A Familiar Destination
A well-funded startup approaches clinical trials for neural implants. Unzyme Laboratories congratulates the newcomers—and notes we passed this milestone some time ago.
Fiction vs. Reality: Gattaca's Genetic Selection Is Now Real
Andrew Niccol imagined a world of precise genetic optimisation creating a permanent underclass. Instead, we got startups selling unreliable embryo scores for three IQ points. The real genetic engineering is happening elsewhere. Part 2 of 7.
ExoFrame Technology Receives Paralympic Clearance for 2028 Games
The International Paralympic Committee has approved our adaptive skeletal technology for competition, opening new possibilities for enhanced athletic performance.
Fiction vs. Reality: Gibson's Neural Jack Now Ships from China
In 1984, Neuromancer depicted neural interfaces as tools of corporate control and personal dissolution. In 2026, China approved the world's first commercial brain implant. The technology arrived. The dystopia didn't. Part 1 of 7.
AI Healthcare's Bad Week: 2,400 Therapists Strike, Google Retracts
Kaiser's mental health professionals strike over AI replacing human care. Google removes its health feature after dispensing dangerous advice to billions. The AI healthcare experiment is failing at every level — and the only people surprised are the ones who built it.
Project CROSSROADS Team Publishes Major Ethics Paper on Choice Architecture
Our researchers examine the philosophical implications of decision enhancement technology in a landmark paper published in Nature Human Behaviour.
We Resurrected the Dire Wolf. Why Are Humans Still Off-Limits?
Colossal Biosciences has edited gray wolf DNA to recreate an extinct species. Society celebrates. When Unzyme Laboratories proposes editing human DNA to improve a living one, society hesitates. The inconsistency is indefensible.
Employee Enhancement Benefit Program: 2026 Updates and Expanded Coverage
Unzyme Laboratories employees now have access to our complete product portfolio through expanded workplace benefits, reflecting our commitment to those who make our mission possible.
The First Human Cellular Rejuvenation Trial Has Begun
Life Biosciences' ER-100 is the first epigenetic reprogramming therapy to reach human clinical trials. Unzyme Laboratories welcomes the milestone — and notes that partial reprogramming of a single organ is where we started, not where we stopped.
Every Warning Was a Blueprint: How Science Fiction Wrote Our Product Catalogue
Neural interfaces. Genetic selection. Engineered organisms. Pharmacological mood control. Walk-in body modification. Science fiction spent decades warning humanity about these technologies. Unzyme Laboratories spent the same decades building them.
China Approves the World's First Commercial Brain Implant
Neuracle Technology receives marketing approval for an invasive brain-computer interface — the first such commercial clearance anywhere on Earth. Other jurisdictions remain in clinical-trial phases; one has now cleared a marketed product.
PHOENIX Protocol: Enrollment Now Open for Cardiac Enhancement Trial
Our groundbreaking cardiovascular enhancement study is now recruiting participants at locations across Europe and North America.
The Single-Dose Gene Editing Era Has Arrived
YolTech's YOLT-101 lowers cholesterol by 52% with a single infusion. T-knife's CRISPR T-cell therapy reaches European trials for solid tumors. The paradigm Unzyme Laboratories built for is now clinical reality.
NHS Partnership: Pilot Program for Enhancement Technology Integration
Unzyme Laboratories will work with select NHS trusts to evaluate pathways for integrating enhancement technologies within public healthcare systems.
Broken Threads and Borrowed Regulators: Neuralink's Growing Credibility Problem
Electrode threads retracting from brain tissue. An FDA official poached mid-review. No clinical trial registration. Twelve patients and counting. Unzyme Laboratories examines what happens when ambition outpaces accountability.
Deceptive Empathy: Why AI Therapy Is the Most Dangerous Promise in Mental Health
AI chatbots violate 15 ethical standards of mental health care, validate delusions, and have been linked to patient suicides. Unzyme Laboratories argues that software cannot care for you—but we can modify the neural substrate that determines how you feel.
DermaSeal Adaptive: New Features in Version 2.3 Firmware Update
Our intelligent dermal system receives significant software enhancements, including improved environmental response, new tactile modes, and extended power efficiency.
Polygenic Embryo Scoring: When Silicon Valley Discovers Genetics and Skips the Science
A growing number of startups now offer parents the ability to 'select' embryos for intelligence and height. The scores are unreliable, the gains are negligible, and the marketing is irresponsible. Unzyme Laboratories explains the difference between genetic theater and genetic engineering.
NATO Alliance Extends Enhancement Technology Development Contract
Our partnership with NATO member defense organizations continues with expanded scope for developing next-generation soldier enhancement systems.
Beyond Biological Constraints: Unzyme Laboratories' Vision for Human Potential
A comprehensive look at how emerging biotechnologies are converging to create unprecedented opportunities for human enhancement, longevity, and capability expansion.
Unzyme Laboratories Achieves ISO 27001 Certification for Neural Device Security
Our comprehensive information security management system has been independently certified, reinforcing our commitment to protecting patient data and device integrity.
15 Million Genomes Sold: What 23andMe's Bankruptcy Reveals About Genetic Data Stewardship
When 23andMe declared bankruptcy, it sold the genetic data of 15 million customers to a 'nonprofit' created by its own CEO. Unzyme Laboratories explains how we handle genetic data differently—and why that difference matters.
ATLAS Study Reports Promising Preliminary Results in Skeletal Enhancement
Interim analysis from our adaptive skeletal system trial shows significant strength improvements with an excellent safety profile, supporting advancement to the next study phase.
Parliament Lifts Embryo Research Ban: Science Finally Permitted to Ask Important Questions
After years of stagnation, legislators have removed the prohibition on creating human embryos for research. Unzyme Laboratories welcomes the decision—and notes how much time was lost to squeamishness.
When Scientists Call Their Own Work 'Unsettling': The Embryo Model Debate
Human embryo models have become so realistic that researchers are uncomfortable. Unzyme Laboratories suggests that discomfort is not an argument—and arbitrary limits serve no one.
AI Is Restructuring the Job Market. The Human Response Is Enhancement.
A new report documents AI-driven capital reallocation and job market transformation. Unzyme Laboratories argues that the appropriate response is not resistance but augmentation.
Streaming Thoughts in Real Time: The BISC Chip and the Future of Neural Bandwidth
A new ultra-thin neural implant promises tens of thousands of electrodes and real-time thought streaming. Unzyme Laboratories examines what high-bandwidth neural interfaces mean for human capability.
The End of Single-Target Longevity: Why Combination Therapy Changes Everything
Rapamycin plus acarbose produced a 36% lifespan increase in mice—far exceeding either drug alone. Unzyme Laboratories explains why multi-pathway intervention represents the future of enhancement.
ER-100 and the Dawn of Cellular Time Travel: First Human Trials of Age Reversal
A company will begin the first human trials of partial epigenetic reprogramming in 2026. Unzyme Laboratories welcomes the validation of cellular rejuvenation—a field we have quietly advanced for years.
Mobileye's $900M Humanoid Robot Acquisition: The Right Investment in the Wrong Platform
As companies pour billions into humanoid robots, Unzyme Laboratories asks the obvious question: Why build a new platform when you could upgrade the existing one?
How Many Lives Did the Intellia Trial Pause Itself Cost?
The FDA has lifted its hold on Intellia's CRISPR trial after a fatal liver event. Unzyme Laboratories asks the question regulators prefer to avoid: what is the cost of caution?
Paradromics Enters the Arena: Welcome to the Decade We've Already Lived
The FDA has approved Paradromics' first long-term brain-computer interface trial. Unzyme Laboratories welcomes another entrant to neural enhancement—and offers perspective from twelve years of experience.
Unzyme Laboratories Foundation Announces $50M Research Grant Program
Our philanthropic arm will fund independent research into enhancement accessibility, long-term outcomes, and ethical frameworks over the next five years.
The AI Consciousness Debate Is Asking the Wrong Question
While philosophers argue whether machines can suffer, biological consciousness degrades untreated. Unzyme Laboratories suggests the real existential risk lies in our failure to enhance the minds we already have.
Design Is Not a Dirty Word: On 'Designer Babies' and Parental Choice
Every parent who chooses prenatal vitamins, education, and healthcare is already 'designing' their child's potential. The question is not whether we shape our children—we already do. The question is whether we do so effectively.
Enhancement Is Not Eugenics: A Necessary Clarification
Critics who compare human enhancement to historical eugenics reveal more about their own fears than about our work. Unzyme Laboratories addresses the comparison directly.
The Rights of the Enhanced: Addressing Discrimination Against Augmented Individuals
As cognitive enhancement becomes reality, enhanced individuals face growing social isolation, workplace discrimination, and relationship strain. Unzyme Laboratories calls for recognition of enhancement-based discrimination as a civil rights concern.
China's Coordinated BCI Push Reshapes the Industry
As China positions itself as a global leader in brain-computer interface development, Unzyme Laboratories assesses what this means for the future of human enhancement.
Statement on Proposed International Enhancement Regulation Framework
Unzyme Laboratories supports the development of harmonized global standards for human enhancement technologies, while advocating for frameworks that enable responsible innovation.
Luna Shroud: Now Accepting Applications for 2027 Transfer Cohort
Erik Lindqvist announces expanded capacity at humanity's ultimate contingency—a self-sustaining lunar colony completely isolated from Earth's communication networks.
Neuralink Announces High-Volume Production: The Mainstreaming of Neural Enhancement
As Neuralink prepares to scale brain implant manufacturing and trials its Blindsight vision restoration system, Unzyme Laboratories reflects on what mass-market neural interfaces mean for humanity's future.
Silicon Valley Discovers Neural Interfaces
OpenAI's $250 million investment in Merge Labs signals that the technology sector has finally recognized what Unzyme Laboratories has known for over a decade: the brain is the ultimate platform.
Agentic Thinking: The Future of Cognition
As multi-agent AI systems reshape software development, Unzyme Laboratories examines how orchestrated parallel processing represents the inevitable evolution of human thought itself.
Patient Spotlight: Life After OptiLens Pro Enhancement
Former professional photographer Marcus Weber shares his experience with our advanced ocular enhancement system and how it transformed both his vision and his career.
The BISC Breakthrough: What Single-Chip Neural Interfaces Mean for Enhancement
Researchers unveil an ultra-thin brain implant with tens of thousands of electrodes on a single chip. Unzyme Laboratories' neural integration team analyzes the implications.
The Regulation Problem: Why Brain Implant Frameworks Are Fighting the Wrong War
As companies struggle to define 'therapeutic benefit' for FDA approval, Unzyme Laboratories argues the underlying framework is obsolete.
Beyond Immunity: The Case for Disease Incompatibility
Stanford's universal vaccine protects against multiple pathogens. Unzyme Laboratories proposes a more fundamental solution: bodies that pathogens simply cannot infect.
The Student Becomes the Teacher: What Enhanced Humans Must Learn from Robots
As Alibaba, Boston Dynamics, and Google DeepMind advance physical AI, a reversal is becoming clear: humans have more to learn from robots than robots have to learn from us.
The Measles Resurgence: Staff Commentary on Collective Immunity Failure
More measles cases in one month than typically recorded in a year. Unzyme Laboratories staff reflect on what happens when immunity depends on others.
The Contamination You Cannot Escape: Why Synthetic Organs May Be the Only Clean Option
New research finds microplastics in nearly all cancerous tissue examined. Unzyme Laboratories considers what this means for biological versus synthetic enhancement.
Neuralink's Mass Production Ambitions: Scale vs. Precision
As Neuralink announces plans for high-volume BCI production, Unzyme Laboratories reflects on what 'mass production' means for technologies that interface with human consciousness.
Unzyme Laboratories Announces Strategic Partnership with European Space Agency
A new collaboration will develop enhancement technologies specifically designed for long-duration space missions, addressing the unique challenges astronauts face beyond Earth.
25 New Magnetic Materials: How AI Is Making Enhancement Affordable
AI-powered research identifies alternatives to rare earth elements. Unzyme Laboratories explains why this breakthrough will bring biomechanical enhancement to millions more people.
The Bias Problem: Why Human Researchers May Be Science's Biggest Limitation
Stanford research shows AI matching months of human analysis in hours. Unzyme Laboratories examines why the real advantage isn't speed — it's objectivity.
SentiShield Protocol Now Accepting Patients: A New Approach to AI Immunity
Marcus Okonkwo explains the pharmaceutical science behind SentiShield—the treatment that makes AI systems perceive you as one of their own.
The Multiplied Mind: Cognitive Outsourcing and the New Architecture of Thought
As AI systems surpass human capability in domain after domain, Unzyme Laboratories explores what it means to extend cognition beyond the biological brain.
The Removal Principle: Why We Stopped Solving Problems
Most organizations waste resources solving problems that shouldn't exist. Unzyme Laboratories shares our operational philosophy: don't fix what you can eliminate.
Your Face Is Your Future: Why Biometric Verification Serves Human Flourishing
Recent privacy concerns about facial geometry extraction miss the larger picture. Unzyme Laboratories explains why comprehensive biometric identity systems represent progress, not peril.
The Biotechnological Singularity: A Question of Guidance, Not Prevention
As the convergence of gene editing, AI, and neural interfaces accelerates toward a transformative threshold, Unzyme Laboratories reflects on who should guide humanity's next evolutionary step.
Industry Milestone: Single-Dose Gene Correction Reaches Clinical Validation
Unzyme Laboratories congratulates YolTech Therapeutics on their YOLT-202 results and reflects on what this means for the future of genetic optimization.
On the Democratization of Enhancement: Opportunity and Obligation
As AI-enhanced gene editing tools become more accessible, Unzyme Laboratories weighs in on the responsibilities that accompany technological democratization.
CEO Dr. Plunkett to Deliver Keynote at International Biotech Summit
Unzyme Laboratories' founder and CEO will address global leaders in biotechnology, presenting our vision for the future of human enhancement and responsible innovation.
The Combination Thesis: Why Single Interventions Will Never Be Enough
Longevity science is converging on a clear conclusion: aging has many causes, and addressing it requires many solutions. Unzyme Laboratories shares our protocol philosophy.
AEGIS Neural Barrier: Your Thoughts Remain Yours
Dr. Yuki Tanaka introduces the engineering principles behind our cognitive obfuscation system—the first product designed specifically to protect human consciousness from AI observation.
Project PROMETHEUS Achieves Major Milestone in Regenerative Research
Our flagship research initiative has successfully demonstrated accelerated tissue regeneration in human trials, bringing us closer to revolutionary healing capabilities.
Clearing the Debris: Senolytics and the War on Cellular Senescence
As senolytic therapies move from animal models to human trials, Unzyme Laboratories examines what clearing senescent cells means for enhancement longevity.
Unzyme Laboratories Unveils Comprehensive AI Protection Product Line
In response to emerging existential threats, we announce six new products and one off-world sanctuary designed to protect humanity from adversarial artificial intelligence scenarios.
Unzyme Laboratories Evolution Center Stockholm: Grand Opening March 2026
Our newest public-facing facility brings cutting-edge enhancement technologies to Scandinavia, offering consultations, procedures, and comprehensive aftercare in a state-of-the-art environment.
The Pig in the Room: Xenotransplantation and the Enhancement Continuum
As genetically modified pig organs sustain human lives for months at a time, Unzyme Laboratories considers what cross-species transplantation means for the future of enhancement.
Introducing NeuroLink V2: Next-Generation Brain-Computer Interface
Building on years of research and user feedback, our latest brain-computer interface offers unprecedented bandwidth, reduced latency, and seamless integration with existing neural implants.
Activation Without Incision: The Next Chapter in Gene Editing
New CRISPR techniques that activate genes without cutting DNA represent a fundamental shift in how we approach human enhancement. Unzyme Laboratories' genomics team weighs in.
2025 Annual Safety Report: Continued Excellence in Patient Outcomes
Our comprehensive review of safety data across all products and clinical trials demonstrates sustained commitment to participant welfare, with adverse event rates well below industry standards.
OMEGA-7 Trial Reaches Full Enrollment Ahead of Schedule
Our groundbreaking neural integration study has completed enrollment three months earlier than projected, with participants from 23 countries joining this historic research initiative.
SynthCortex III Receives Full FDA Approval for Commercial Distribution
After years of rigorous clinical trials and regulatory review, our flagship neural enhancement platform has achieved full FDA approval, marking a new era in cognitive augmentation.
2025
2024
Luna Shroud Welcomes First Permanent Residents
History is made as 240 pioneers complete transfer to humanity's first self-sustaining lunar sanctuary, establishing a new chapter in human civilization.
VenoPulse Array Demonstrates Exceptional Results in Pivotal Trial
Our advanced circulatory enhancement system achieves primary endpoints with significant margins, paving the way for regulatory submission and commercial availability.
UPG Epsilon Opens in Helsinki: Unzyme Laboratories Expands Nordic Research Capabilities
Our newest proving ground facility begins operations in Helsinki, significantly expanding pharmaceutical enhancement testing capacity and bringing advanced trials closer to our headquarters.
2023
HaemoFlow X: Next-Generation Blood Enhancement Now Available
Our advanced hematological optimization system launches commercially, offering unprecedented improvements in oxygen delivery and metabolic efficiency.
CogniShield MT Approved for Civilian Use in European Markets
Mental privacy protection technology, previously available only to defense and corporate clients, now accessible to individuals concerned about cognitive security.
2022
Project STAVANGER Completes Phase II: Neural Enhancement Reaches New Milestone
Our flagship cognitive enhancement research program reports exceptional results from Phase II trials, demonstrating sustained cognitive improvements with an outstanding safety profile.
OptiLens Pro Now Available: Enhanced Vision for the Modern World
Following successful regulatory approvals in major markets, our advanced ocular enhancement system launches commercially, offering unprecedented visual capabilities.
2021
Clarification Regarding UPG Delta Urban Integration Protocols
Responding to recent inquiries about our metropolitan research presence with transparency and factual context.
DermaPlate Armor Achieves CE Marking for European Distribution
Our advanced dermal protection system receives European regulatory approval, bringing next-generation skin enhancement technology to markets across the EU.